Skip to main content
. 2021 Mar 3;19(3):e06419. doi: 10.2903/j.efsa.2021.6419

Table 4.

Case‐fatality rate observed during experimental infections

Experimental animal group Reference ASFV genotype II strain Target Sample size Route Doses Duration (dpi) Died due to disease Euthanised due to disease Case‐fatality rate
1 Bernard et al. (2016) Ambaton 02 DP 18 ID 104 HAD50 8 0 18 100
2 Bernard et al. (2016) Ambaton 02 DP 12 ID 102 HAD50 8 0 12 100
3 Pietschmann et al. (2015) Armenia 08 WB 6 ON 10 HAD50 36 6 0 100
4 Pietschmann et al. (2015) Armenia 08 DP 6 ON 100 HAD50 36 6 0 100
5 Pietschmann et al. (2015) Armenia 08 DP 6 ON 10 HAD50 36 6 0 100
6 Pietschmann et al. (2015) Armenia 08 WB 6 ON 100 HAD50 36 6 0 100
7 Frederic et al. (2015) Georgia 2007/1 DP 3 IM 103 TCID50 6 3 0 100
8 Vlasova et al. (2015) Kashino 04/13 DP 4 IH 50 HAD50 21 4 0 100
9 Vlasova et al. (2015) Kashino 04/13 DP 2 DC 503 HAD50 15 2 0 100
10 Vlasova et al. (2015) Boguchary 06/13 DP 4 IH 50 HAD50 11 4 0 100
11 Vlasova et al. (2015) Boguchary 06/13 DP 2 IM 503 HAD50 9 2 0 100
12 Vlasova et al. (2015) Boguchary 06/13 DP 2 DC 503 HAD50 9 2 0 100
13 Vlasova et al. (2015) Karamzino 06/13 DP 4 IH 50 HAD50 21 4 0 100
14 Vlasova et al. (2015) Karamzino 06/13 DP 2 IM 503 HAD50 11 2 0 100
15 Vlasova et al. (2015) Karamzino 06/13 DP 2 DC 503 HAD50 15 2 0 100
16 Vlasova et al. (2015) K 08/13 DP 4 IM 503 HAD50 11 4 0 100
17 Vlasova et al. (2015) Vyazma 08/13 DP 4 IH 50 HAD50 15 4 0 100
18 Vlasova et al. (2015) Vyazma 08/13 DP 2 IM 503 HAD50 8 2 0 100
19 Vlasova et al. (2015) Stavropol 01/08 DP 4 IH 50 HAD50/503 HAD50 9 4 0 100
20 Guinat et al. (2014) Georgia 2007/1 DP 16 DC 14 0 16 100
21 Guinat et al. (2014) Georgia 2007/1 DP 16 DC 18 0 16 100
22 Guinat et al. (2014) Georgia 2007/1 DP 16 IM 102 HAD50 12 1 15 100
23 Karalyan et al. (2012) Field strain from Armenia and Georgia DP 9 IM 7 9 100
24 Gabriel et al. (2011) Armenia/2008 WB 1 IM 103 HAD50 25 1 0 100
25 Gabriel et al. (2011) Armenia/2008 WB 3 DC NA 25 3 0 100
26 Gabriel et al. (2011) Armenia/2008 DP 3 DC NA 20 3 0 100
27 Gabriel et al. (2011) Armenia/2008 WB 6 O 25 6 0 100
28 Olesen et al., (2018) POL/2015/Podlaskie/Lindholm DP 4 DC 7 0
29 Olesen et al. (2018) POL/2015/Podlaskie/Lindholm DP 4 DC NA 21 0
30 Olesen et al. (2018) POL/2015/Podlaskie/Lindholm DP 4 DC NA 21 0
31 Olesen et al. (2018) POL/2015/Podlaskie/Lindholm DP 4 DC 106 MTC 21 0
32 Olesen et al. (2017) POL14/WB7397#13 DP 4 DC NA 14 0 4 100
33 Olesen et al. (2017) POL14/WB7397#13 DP 6 DC NA 18 2 33.3
34 Olesen et al. (2017) POL14/WB7397#13 DP 4 IN 104.5 TCID50 11 0 4 100
35 Olesen et al. (2017) POL14/WB7397#13 DP 4 DC NA 12 0 4 100
36 Olesen et al. (2017) POL14/WB7397#13 DP 4 DC NA 12 0 4 100
37 Olesen et al. (2017) POL14/WB7397#13 DP 4 DC NA 14 1 2 75
38 Olesen et al. (2017) POL14/WB7397#13 DP 4 IN 104.5 TCID50 11 1 3 100
39 Olesen et al. (2017) POL14/WB7397#13 DP 4 DC NA 16 2 50
40 Olesen et al. (2017) POL14/WB7397#13 DP 4 DC NA 14 0 4 100
41 Karalyan et al. (2017) NR DP 8 IM 104 HAD50 7 0 8 100
42 Gallardo et al. (2017) LT14/1490 DP 8 IM No pdf 19 8 0 100
43 Gallardo et al. (2017) LT14/1490 DP 10 DC NA 61 9 0 90
44 Popescu et al. (2017) Georgia 2007/1 DP 10 IM 104 HAD50 4 0 10 100
45 Donnell et al. (2016) Georgia 2007 DP 5 IM 103 HAD50 8 0 5 100
46 Donnell et al. (2016) Georgia 2007 DP 5 IM 103 HAD50 0 5 100
47 Donnell et al. (2016) Georgia 2007 DP 5 IM 103 HAD50 9 0 5 100
48 Donnell et al. (2017) Georgia DP 5 IM 104 HAD50 7 0 5 100
49 Donnell et al. (2017) Georgia DP 5 IM 104 HAD50 7 0 5 100
50 Burmakina et al. (2016) Congo K‐49 DP 3 IM 103 HAU 6 3 0 100
51 Burmakina et al. (2016) Congo K ‐49 DP 3 IM 103 HAU 7 3 0 100
52 Burmakina et al. (2016) Congo K ‐49 DP 3 IM 103 HAU 8 3 0 100
55 Sanford et al. (2016) Georgia DP 2 IM 104 TCID50 8 0 2 100
56 Sanford et al. (2016) Georgia DP 5 IM 104 TCID50 8 0 5 100
57 Gallardo et al. (2018) Es15/WB‐Tartu14 ASFV DP 2 IM 10 HAD50 78 2 0 100
58 Gallardo et al. (2018) Es15/WB‐Valga‐6 ASFV DP 2 IM 10 HAD50 78 1 1 100
59 Gallardo et al. (2018) Es15/WB‐Tartu14 ASFV DP 4 DC NA 78 2 0 50
60 Gallardo et al. (2018) Es15/WB‐Valga‐6 ASFV DP 4 DC NA 78 2 0 50
61 Zani et al. (2018) ASFV from N‐E Estonia mini‐DP 12 ON 105 HAU 36 1 2 25
62 Zani et al. (2018) ASFV from N‐E Estonia DP 5 ON 105 HAU 36 0 0 0
63 Zani et al. (2018) ASFV from N‐E Estonia WB 5 ON 106.5 HAU 17 2 3 100
64 Zhao et al. (2019) DP/HLJ/18 DP 1 IM NR 14 1 0 100
65 Zhao et al. (2019) DP/HLJ/18 DP 2 IM NR 14 2 0 100
66 Zhao et al. (2019) DP/HLJ/18 DP 3 IM NR 14 3 0 100
67 Zhao et al. (2019) DP/HLJ/18 DP 3 IM NR 14 3 0 100
68 Zhao et al. (2019) DP/HLJ/18 DP 2 DC NR 14 2 0 100
69 Gallardo et al. (2019) Lv17/WB/Rie1 (non‐HAD) DP 2 IM 10 TCID50 126 0 1 50
70 Gallardo et al. (2019) Lv17/WB/Rie1 (non‐HAD) DP 4 DC NA 126 0 3 75
71 Gallardo et al. (2019) Lv17/WB/Zieme3 (HAD) DP 1 IM 10 TCID50 126 1 100
72 Gallardo et al. (2019) Lv17/WB/Zieme3 (HAD) DP 1 DC NA 126 0 1 100
73 Cadenas‐Fernandez et al. (2020) ASFV Arm07 isolate WB 2 IM 10 HAD50 48 0 2 100
74 Walczak et al. (2020) Pol18_28298_O111 DP 8 IN 1000 HAU 32 7 0 87.5
75 Walczak et al. (2020) Pol18_28298_O111 DP 6 IN 500 HAU 24 4 2 100
76 Walczak et al. (2020) Pol18_28298_O111 DP 8 IN 5 HAU 21 6 2 100
77 Borca et al. (2020) Georgia 2007/1 DP 5 IM 102 HAD50 0 5 100
78 Lokhandwala et al. (2019) ASFV‐Georgia 2007/1 DP 5 IN 104 TCID50 5 1 2 60
79 Lokhandwala et al. (2019) ASFV‐Georgia 2007/1 DP 5 IN 104 TCID50 5 2 1 60

DC: direct contact with infected animals; DP: domestic pig; dpi: days post‐inoculations; HAD: haemadsorption doses; HAU: haemadsorbing units; ID: intradermal; IH: inhalation; IM: intramuscular; IN: intranasal; MTC: Maximum tolerable concentration; NA: not applicable; NR: not reported; O: oral; ON: oronasal; TCID: tissue culture infectious dose; V: vector bite; WB: wild boar.